-- First patient dosed in global Phase 1/2 clinical trial of PM577a in Wilson disease, the first clinical study of an in vivo Prime Editing therapy from Prime Medicine; initial clinical data expected in 2027 --
-- Received FDA clearance of Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency; initial clinical data expected in 2027 --
-- Planning for a BLA submission for PM359 in the first half of 2027 --
-- Closed underwritten public offering, including the full exercise of the underwriters’ option to purchase additional shares, raising
-- Pro-forma cash, cash equivalents, investments and restricted cash of approximately
“Prime Medicine continued to make significant progress this quarter, highlighted by dosing the first patient in our Phase 1/2 trial of PM577a for Wilson disease, our first clinical study of an in vivo Prime Editing therapy,” said
Recent Corporate Updates:
Wilson Disease (PM577a)
In
The Phase 1/2 clinical trial (NCT07748403) is an open-label, global, first-in-human study designed to evaluate the safety, tolerability, and preliminary clinical efficacy of ascending doses of PM577a in adults and adolescents with Wilson disease containing at least one p.H1069Q allele in the ATP7B gene. The study is initially enrolling adults who are clinically stable on standard-of-care therapy. Initial clinical data are expected in 2027.
PM577a is the first program in the PM577 family, a portfolio of Wilson disease medicines designed to address genetically defined patient populations worldwide using a shared LNP delivery platform. A follow-on candidate targeting the R778L mutation, the most prevalent Wilson disease-causing variant in East Asian populations, is in preclinical development. Additional efforts are underway to develop Prime Editors targeting other prevalent mutations.
Alpha-1 Antitrypsin Deficiency (PM647)
In
The Phase 1/2 clinical trial will be a global, single-arm, open-label, first-in-human study designed to evaluate the safety, tolerability and preliminary clinical efficacy of ascending doses of a one-time intravenous infusion of PM647 in adults with AATD. The study will initially enroll adult participants with lung-only manifestations of AATD and, upon demonstration of tolerability, will expand to include a separate cohort enrolling adults with significant liver disease, with or without concurrent lung manifestations of AATD. Initial clinical data are expected in 2027.
Chronic Granulomatous Disease (PM359)
PM359 has received Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA. Prime Medicine continues to engage with the FDA on the most efficient path to approval, with a BLA submission planned for the first half of 2027.
Other Pipeline Programs
Prime Medicine continues to advance its in vivo Cystic Fibrosis (CF) program with support from the
The Company is also advancing Prime Edited ex vivo CAR-T products for hematology, immunology and oncology in partnership with Bristol Myers Squibb. The collaboration brings together Prime Medicine’s Prime Editing and PASSIGE technologies and Bristol Myers Squibb’s cell therapy expertise to develop next-generation therapies for immunological diseases and cancer.
Corporate Financing
In
Upcoming Milestones
- Continue enrollment in the global Phase 1/2 clinical trial of PM577a in Wilson disease; initial clinical data in 2027.
- Initiate Phase 1/2 clinical trial of PM647 in AATD; initial clinical data in 2027.
- Submit BLA for PM359 in the first half of 2027.
Third Quarter 2026 Financial Results
- Research and Development (R&D) Expenses: R&D expenses were
$34 .1 million for the three months endedSeptember 30, 2026 , as compared to$44 .0 million for the three months endedSeptember 30, 2025 . R&D expenses in third quarter of 2025 were higher due to the issuance of restricted stock units in that quarter. Further, facility cost related to lab equipment repair and maintenance decreased during the third quarter of 2026. - General and Administrative (G&A) Expenses: G&A expenses were
$10 .0 million for the three months endedSeptember 30, 2026 , as compared to$11 .2 million for the three months endedSeptember 30, 2025 . The decrease in G&A expenses was primarily driven by lower corporate legal fees. - Net Loss: Net loss was
$39 .0 million for the three months endedSeptember 30, 2026 , as compared to$50 .6 million for the three months endedSeptember 30, 2025 . - Cash Position: As of
September 30, 2026 , cash, cash equivalents, investments, and restricted cash were$74 .8 million, as compared to$191 .4 million as ofDecember 31, 2025 .
Financial Guidance
Based on its current operating plans, Prime Medicine expects that its cash, cash equivalents and investments as of
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.
From time to time Prime Medicine may use its website, its X, formerly Twitter, account (@PrimeMedicine) or its LinkedIn profile at https://www.linkedin.com/company/prime-medicine to distribute material information. Its financial and other material information is routinely posted to and accessible on the Investors section of its website, available at www.primemedicine.com. Investors are encouraged to review the Investors section of its website because the Company may post material information on that site that is not otherwise disseminated by the Company. Information that is contained in and can be accessed through the Company’s website or its social media is not incorporated into, and does not form a part of, this press release.
© 2026 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the continued development and advancement of its Wilson disease and AATD programs, including the continued enrollment in the global Phase 1/2 clinical trial of PM577a, the initiation and design of the Phase 1/2 clinical trial of PM647, and initial clinical data for both programs in 2027; the expansion of its liver franchise, including the development of PM577b and other follow-on candidates targeting prevalent Wilson disease mutations and potential expansion into additional indications; the ongoing regulatory engagement with the FDA based on the data from its Phase 1/2 trial of PM359 and the outcomes of such engagement, including the planned submission of a BLA in the first half of 2027; the potential of Prime Editing to correct the causative mutations of, and to cure, diseases, including Wilson disease, AATD, CF, and CGD; the potential impact of the FDA’s draft guidance on individualized genome editing if finalized, including on the Company’s ability to extend Prime Editing therapies to additional diseases; the modularity of the Prime Editing platform and versatility of the universal liver LNP platform, and the benefits thereof; its expectations regarding the breadth of Prime Editing technology and the implementation of its strategic plans for its business, programs, and technology; the potential of Prime Editing to unlock opportunities across thousands of potential indications; its intended use of net proceeds from its recent public offering; and its expected cash runway.
Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
gdearborn@primemedicine.com
Hannah Deresiewicz
Precision AQ
212-362-1200
hannah.deresiewicz@precisionaq.com
| Condensed Consolidated Balance Sheet Data (unaudited) | ||||||
| (in thousands) | 2026 | 2025 | ||||
| Cash, cash equivalents, and investments | $ | 61,157 | $ | 177,680 | ||
| Total assets | $ | 213,855 | $ | 342,733 | ||
| Total liabilities | $ | 205,418 | $ | 221,865 | ||
| Total stockholders’ equity | $ | 8,437 | $ | 120,868 | ||
| Condensed Consolidated Statement of Operations (unaudited) | ||||||||
| Three Months Ended | ||||||||
| (in thousands, except share and per share amounts) | 2026 | 2025 | ||||||
| Revenue: | ||||||||
| Collaboration revenue — related party | $ | 4,213 | $ | 1,179 | ||||
| Collaboration revenue | — | 46 | ||||||
| Total revenue | 4,213 | 1,225 | ||||||
| Operating expenses: | ||||||||
| Research and development | 34,117 | 43,990 | ||||||
| General and administrative | 10,022 | 11,208 | ||||||
| Total operating expenses | 44,139 | 55,198 | ||||||
| Loss from operations | (39,926 | ) | (53,973 | ) | ||||
| Other income: | ||||||||
| Interest income | 555 | 1,141 | ||||||
| Accretion (amortization) of investments | 274 | 752 | ||||||
| Change in fair value of short-term investment — related party | — | 1,454 | ||||||
| Other income, net | 54 | 44 | ||||||
| Total other income, net | 883 | 3,391 | ||||||
| Net loss attributable to common stockholders | $ | (39,043 | ) | $ | (50,582 | ) | ||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.22 | ) | $ | (0.32 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 177,857,047 | 160,503,183 | ||||||
Source: 